Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III
Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...
Top 3 Price Prediction Bitcoin, Ethereum, Ripple: BTC, ETH and XRP recovery could be short-lived
Bitcoin (BTC) price hovers around $104,000 on Friday after bouncing off from its 50-day Exponential Moving Average (EMA) of ...
GlobalData on MSN13h
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities
KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the ...